Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Non Operating Income: 2020-2025

Historic Non Operating Income for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to $223,000.

  • Insight Molecular Diagnostics' Non Operating Income rose 320.75% to $223,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $651,000, marking a year-over-year increase of 11.28%. This contributed to the annual value of $462,000 for FY2024, which is 17.26% up from last year.
  • Per Insight Molecular Diagnostics' latest filing, its Non Operating Income stood at $223,000 for Q3 2025, which was up 78.40% from $125,000 recorded in Q2 2025.
  • Insight Molecular Diagnostics' Non Operating Income's 5-year high stood at $1.3 million during Q2 2021, with a 5-year trough of -$919,000 in Q4 2022.
  • In the last 3 years, Insight Molecular Diagnostics' Non Operating Income had a median value of $127,000 in 2023 and averaged $130,273.
  • Its Non Operating Income has fluctuated over the past 5 years, first spiked by 476.76% in 2021, then crashed by 750.93% in 2022.
  • Insight Molecular Diagnostics' Non Operating Income (Quarterly) stood at -$108,000 in 2021, then plummeted by 750.93% to -$919,000 in 2022, then soared by 129.27% to $269,000 in 2023, then tumbled by 45.72% to $146,000 in 2024, then skyrocketed by 320.75% to $223,000 in 2025.
  • Its Non Operating Income stands at $223,000 for Q3 2025, versus $125,000 for Q2 2025 and $157,000 for Q1 2025.